Olive Garden Raises $2 Million for Leukemia Society

Publication
Article
OncologyONCOLOGY Vol 11 No 11
Volume 11
Issue 11

Olive Garden Italian Restaurants recently reached their goal of raising $2 million through its “Pasta for Pennies” program to

Olive Garden Italian Restaurants recently reached their goal of raising $2 million through its “Pasta for Pennies” program to benefit the Leukemia Society of America. The program encourages elementary, middle, and high school students around the country to donate any spare change they can find. The class that raises the most money receives a pasta lunch from the restaurant chain.

More than 1,500 schools nationwide recently contributed their spare change to help Olive Garden reach this year’s goal. “We salute students, teachers, and parents for their participation in “Pasta for Pennies,” said Brad Blum, President of the Olive Garden Italian Restaurant.

More than 290 Olive Garden Restaurants participated in “Pasta for Pennies” this year. In addition to a pasta lunch, schools have the chance to win such prizes as computers, televisions, and educational trips. Olive Garden further supports the program by hosting kick-off luncheons for participating schools and providing market support.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content